Published Sep 19, 2026
Metagenomi Therapeutics (MGX): Genome Editing Narrows to One Hemophilia Bet
In-depth research on MGX covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,637 words16 min read
Read report